Vogenx Q3 2026 Results: Net Loss of $4.91M, Loss Widens
Vogenx, Inc. is a clinical-stage biopharmaceutical company that has incurred significant losses since inception and expects to continue doing so for the foreseeable future. The company currently generates no revenue from product sales and requires substantial additional funding to advance its research and development programs, including its lead candidate mizagliflozin.
- Key figure
- Net loss $4.91M